Søgeord (omicron) valgt.
10 emner vises.
1
Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron—results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP)
Infection, 8.05.2024
Tilføjet 8.05.2024
Abstract Purpose The influence of new SARS-CoV-2 variants on the post-COVID-19 condition (PCC) remains unanswered. Therefore, we examined the prevalence and predictors of PCC-related symptoms in patients infected with the SARS-CoV-2 variants delta or omicron. Methods We compared prevalences and risk factors of acute and PCC-related symptoms three months after primary infection (3MFU) between delta- and omicron-infected patients from the Cross-Sectoral Platform of the German National Pandemic Cohort Network. Health-related quality of life (HrQoL) was determined by the EQ-5D-5L index score and trend groups were calculated to describe changes of HrQoL between different time points. Results We considered 758 patients for our analysis (delta: n = 341; omicron: n = 417). Compared with omicron patients, delta patients had a similar prevalence of PCC at the 3MFU (p = 0.354), whereby fatigue occurred most frequently (n = 256, 34%). HrQoL was comparable between the groups with the lowest EQ-5D-5L index score (0.75, 95% CI 0.73–0.78) at disease onset. While most patients (69%, n = 348) never showed a declined HrQoL, it deteriorated substantially in 37 patients (7%) from the acute phase to the 3MFU of which 27 were infected with omicron. Conclusion With quality-controlled data from a multicenter cohort, we showed that PCC is an equally common challenge for patients infected with the SARS-CoV-2 variants delta and omicron at least for the German population. Developing the EQ-5D-5L index score trend groups showed that over two thirds of patients did not experience any restrictions in their HrQoL due to or after the SARS-CoV-2 infection at the 3MFU. Clinical Trail registration The cohort is registered at ClinicalTrials.gov since February 24, 2021 (Identifier: NCT04768998).
Læs mere
Tjek på PubMed
2
Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China
Xin‐Jing Zhao, Xiao‐Lin Liu, Yu‐Min Liang, Sheng Zhang, Ti Liu, Li‐Bo Li, Wen‐Guo Jiang, Jin‐Jin Chen, Qiang Xu, Chen‐Long Lv, Bao‐Gui Jiang, Zeng‐Qiang Kou, Guo‐Lin Wang, Li‐Qun Fang
Journal of Medical Virology, 4.05.2024
Tilføjet 4.05.2024
3
Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China
Xin‐Jing Zhao, Xiao‐Lin Liu, Yu‐Min Liang, Sheng Zhang, Ti Liu, Li‐Bo Li, Wen‐Guo Jiang, Jin‐Jin Chen, Qiang Xu, Chen‐Long Lv, Bao‐Gui Jiang, Zeng‐Qiang Kou, Guo‐Lin Wang, Li‐Qun Fang
Journal of Medical Virology, 4.05.2024
Tilføjet 4.05.2024
4
Correction: SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
Infection, 1.05.2024
Tilføjet 1.05.2024
5
Correction: SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
Infection, 29.04.2024
Tilføjet 29.04.2024
6
Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study
Siyue JiaZundong YinHongxing PanFuzhen WangXiaoqiang LiuQing WangLi ZhangJihai TangHao YangJiangbo DuZhiguo WangPengfei JinZhihang PengRong TangGuodong KangXuewen WangSimin LiWeixiao WangJingxin LiHongbing ShenFengcai Zhua NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People’s Republic of Chinab National Vaccine Innovation Platform and Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of Chinac China Center for Disease Control and Prevention, Beijing, People’s Republic of Chinad Yunnan Provincial Center for Disease Control and Prevention, Kunming, People’s Republic of Chinae Chongqing Provincial Center for Disease Control and Prevention, Chongqing, People’s Republic of Chinaf Shandong Provincial Center for Disease Control and Prevention, Jinan, People’s Republic of Chinag Anhui Provincial Center for Disease Control and Prevention, Hefei, People’s Republic of Chinah Hunan Provincial Center for Disease Control and Prevention, Changsha, People’s Republic of Chinai School of Public Health, Southeast University; Nanjing, People’s Republic of Chinaj Canming Medical Technology Co., Ltd, Shanghai, People’s Republic of China
Emerg Microbes Infect, 29.04.2024
Tilføjet 29.04.2024
7
Antibiotics daptomycin interacts with S protein of SARS-CoV-2 to promote cell invasion of Omicron (B1.1.529) pseudovirus
Xu CaoLan HuangMin TangYue LiangXinpeng LiuHuijin HouShufang LiangDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
Virulence, 25.04.2024
Tilføjet 25.04.2024
8
Antibody titers and the risk of infection during the SARS-CoV-2 Omicron phase in Bizen City, Japan
Journal of Infectious Diseases, 25.04.2024
Tilføjet 25.04.2024
Abstract Background Understanding the association between the immune response and the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has implications for forthcoming prevention strategies. We evaluated the association between antibody titers and the risk of infection for the general population during the Omicron-dominant phase.Methods This was a prospective cohort study of residents or people affiliated with institutions in Bizen City, which included 1,899 participants. We measured the titers of antibodies against SARS-CoV-2 repeatedly every 2 months from June 2022 to March 2023. Infection status was obtained from self-reported questionnaires and the official registry. We estimated risk ratios (RRs) for infection within 2 months of the date of each antibody measurement with 95% confidence intervals (CIs) based on antibody titer categories and spline functions.Results Compared with the
Læs mere
Tjek på PubMed
9
The contributions of vaccination and natural infection to the production of neutralizing antibodies against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) prototype strain and variants
Hui Xie, Junnan Zhang, Shuang Bai, Min Lv, Juan Li, Weixin Chen, Luodan Suo, Meng Chen, Wei Zhao, Shanshan Zhou, Jian Wang, Ao Zhang, Jianxin Ma, Fengshuang Wang, Le Yan, Dongmei Li, Jiang Wu
International Journal of Infectious Diseases, 25.04.2024
Tilføjet 25.04.2024
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel coronavirus responsible for the coronavirus disease 2019 (COVID-19) global pandemic [1-3]. As the pandemic progressed, new, more transmissible but less virulent variants, like the Omicron variant, emerged and became more dominant, further reducing the mortality rate [4-8]. The World Health Organization (WHO) eventually declared that the COVID-19 pandemic no longer constitutes a public health emergency of international concern on May 2023 [9].
Læs mere
Tjek på PubMed
10
Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination
BMC Infectious Diseases, 25.04.2024
Tilføjet 25.04.2024
Abstract Background Studies have shown that Omicron breakthrough infections can occur at higher SARS-CoV-2 antibody levels compared to previous variants. Estimating the magnitude of immunological protection induced from COVID-19 vaccination and previous infection remains important due to varying local pandemic dynamics and types of vaccination programmes, particularly among at-risk populations such as health care workers (HCWs). We analysed a follow-up SARS-CoV-2 serological survey of HCWs at a tertiary COVID-19 referral hospital in Germany following the onset of the Omicron variant. Methods The serological survey was conducted in January 2022, one year after previous surveys in 2020 and the availability of COVID-19 boosters including BNT162b2, ChAdOx1-S, and mRNA-1273. HCWs voluntarily provided blood for serology and completed a comprehensive questionnaire. SARS-CoV-2 serological analyses were performed using an Immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA). Antibody levels were reported according to HCW demographic and occupational characteristics, COVID-19 vaccination and SARS-CoV-2 infection history, and multivariate linear regression was used to evaluate these associations. Results In January 2022 (following the fourth COVID-19 wave in Germany including the onset of the Omicron variant), 1482/1517 (97.7%) HCWs tested SARS-CoV-2 seropositive, compared to 4.6% in December 2020 (second COVID-19 wave). Approximately 80% had received three COVID-19 vaccine doses and 15% reported a previous laboratory-confirmed SARS-CoV-2 infection. SARS-CoV-2 IgG geometric mean titres ranged from 335 (95% Confidence Intervals [CI]: 258–434) among those vaccinated twice and without previous infection to 2204 (95% CI: 1919–2531) among those vaccinated three times and with previous infection. Heterologous COVID-19 vaccination combinations including a mRNA-1273 booster were significantly associated with the highest IgG antibody levels compared to other schemes. There was an 8-to 10-fold increase in IgG antibody levels among 31 HCWs who reported a SARS-CoV-2 infection in May 2020 to January 2022 after COVID-19 booster vaccination. Conclusions Our findings demonstrate the importance of ongoing COVID-19 booster vaccination strategies in the context of variants such as Omicron and despite hybrid immunity from previous SARS-CoV-2 infections, particularly for at-risk populations such as HCWs. Where feasible, effective types of booster vaccination, such as mRNA vaccines, and the appropriate timing of administration should be carefully considered.
Læs mere
Tjek på PubMed